GUFIC BIOSCIENCES LTD.

Gufic Biosciences Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item is the consideration and approval of the company's Unaudited Financial Results for the quarter ended June 30, 2026. These results will be presented on both a standalone and consolidated basis. Additionally, the company confirmed that the trading window for its equity shares will remain closed until 48 hours after the declaration of these financial results, in line with SEBI regulations and the company's insider trading code.

Gufic Biosciences Ltd's Board of Directors, at its meeting on July 31, 2026, approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as the Whole Time Director. The new term will be for five years, effective from September 7, 2026, to September 6, 2031. This re-appointment is contingent upon the approval of shareholders at the upcoming 42nd Annual General Meeting. Mr. Gandhi possesses over three decades of experience in regulatory liaison within the pharmaceutical industry and is not debarred by SEBI or related to any other directors of the company.

Gufic Biosciences Ltd announced the outcome of its Board of Directors meeting held on July 31, 2026. The board approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director for a further term of 5 years, effective September 7, 2026, subject to shareholder approval. Mr. Gandhi's reappointment is for a term ending September 6, 2031. He is confirmed not to be debarred by any regulatory authority. Mr. Gandhi holds a Bachelor's degree in Commerce and possesses over three decades of experience in the pharmaceutical industry, particularly in liaising with regulatory authorities. He is not related to any other directors of the company.

Gufic Biosciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from Wednesday, July 01, 2026, until 48 hours after the declaration of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The specific date for the Board of Directors' meeting to approve these results will be communicated separately.

Gufic Biosciences Ltd has issued a clarification regarding its subscription to shares of Saraswat Co-operative Bank Limited. The company states that this subscription is not an acquisition or investment but is related to share-linkage requirements for borrower members, as mandated by RBI guidelines for co-operative banks. Gufic Biosciences is an existing borrower with credit facilities of approximately ₹230 crore. The subscription is within permissible limits and does not alter management, control, or voting rights, adhering to the 'one member, one vote' principle of Saraswat Bank.

Gufic Biosciences has issued a corrigendum to clarify its subscription to shares of Saraswat Co-operative Bank Limited. The company stated that the subscription is a mandatory share-linkage requirement for its existing credit facilities of approximately ₹230 crore, as per RBI norms for borrower members. The company emphasized that this transaction does not constitute an acquisition, strategic investment, or change in control, as the bank operates under a 'one member, one vote' principle.

Gufic Biosciences Ltd's board approved a further investment of ₹5.75 Crores in Saraswat Co-operative Bank Limited by subscribing to 57,50,800 equity shares with a face value of ₹10 each. This investment aims to strengthen the existing banking relationship and credit exposure, aligning with the company's investment and treasury management strategy. The acquisition is not a related party transaction, and no promoter group has an interest in it. Post-acquisition, Gufic will hold 57,58,300 shares in Saraswat Bank.

Gufic Biosciences Ltd. has re-appointed M/s. Poddar & Co. as Cost Auditors and appointed Mrs. Saroj R. Kirdolia as Internal Auditor, both effective for the Financial Year 2026-27. The decisions were made during the Board of Directors meeting held on May 29, 2026. M/s. Poddar & Co. is a specialized Cost Accounting firm, while Mrs. Saroj Kirdolia is a Chartered Accountant with experience in auditing and taxation, and has been associated with the company for the past 6 years.

Gufic Biosciences Ltd's Board of Directors, in its meeting held on May 29, 2026, recommended a final dividend of 10%, which is Re. 0.10 per equity share with a face value of Re. 1 each, for the financial year ended March 31, 2026. The dividend is subject to the approval of shareholders at the upcoming Annual General Meeting and will be paid within the statutory timelines as per the Companies Act, 2013. The board meeting commenced at 7:30 p.m. and concluded at 9:05 p.m.

Gufic Biosciences Ltd announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 29, 2026. The company's revenue from operations for the year ended March 31, 2026, stood at ₹94,047.54 Lakhs (Standalone) and ₹94,400.66 Lakhs (Consolidated). The Board meeting commenced at 7.30 p.m. and concluded at 9.05 p.m.